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General Considerations (Synthesis) Reagents and solvents were obtained from commercial sources and 
were used without further purification unless otherwise stated (including anhydrous solvents). Heptane was 
dried with and kept over activated 3Å MS. All reactions were performed in dried glassware (flame-dried or 
oven-dried overnight) under an argon atmosphere unless otherwise stated and monitored by TLC on silica- 
coated plates using solvent mixtures appropriate to each reaction. All column chromatography was 
performed on silica gel (40-63 μm). For compounds containing a basic nitrogen, Et3N was often used in the 
mobile phase in order to provide better resolution. In these cases, TLC plates were pre-soaked in the Et3N-
containing solvent and then allowed to dry briefly before use in analysis, such that an accurate 
representation of Rf was obtained. Nuclear magnetic resonance spectra were recorded on 400 or 500 MHz 
instruments as indicated and collected via the Bruker Topspin software (Bruker Topspin 3.5 pl 6). The 
NMR spectra were analyzed using Mestronova 14.2.0 software. Chemical shifts are reported as δ values in 
ppm referenced to CDCl3 (1H NMR = 7.26 and 13C NMR = 77.16) and CD3OD (1H NMR = 3.31 and 13C 
NMR = 49). Multiplicity is indicated as follows: s (singlet); d (doublet); t (triplet); q (quartet); dd (doublet 
of doublets); dt (doublet of triplets); td (triplet of doublets); m (multiplet); br (broad). In some cases, spectra 
are complicated by the presence of multiple conformers, resulting in peak broadening or additional splitting. 
As a result of these effects, multiple peaks may correspond to the same proton group or carbon atom. When 
possible, this is indicated by an "and" joining two listed peaks or spectral regions. All carbon peaks are 
rounded to one decimal place unless such rounding would cause two close peaks to become identical. In 
these cases, two decimal places are retained. Low resolution mass spectra (LRMS) were recorded on a 
quadrupole mass spectrometer (ionization mode: APCI+ or ESI+). High-resolution mass spectra (HRMS) 
were recorded on a quadrupole time-of-flight mass spectrometer (ionization mode: ESI+). Reactions in 
vials at elevated temperature were performed in an aluminum heating block and the temperature was 
regulated by a thermometer immersed in a vial containing silicon oil. Mitragynine (MG) was obtained by 
extraction and purification from commercially available kratom (Mitragyna speciosa) leaf powder as 
previously described.1,2  
 
Synthetic procedures:  
 
Optimization of C12-selective borylation reactions of MG and subsequent transformations 
 
Supplementary Figure 1: Known C10/C12 derivatization versus unknown C11 derivatization 
 
3 
Supplementary Table 1: A comprehensive overview of borylation optimization reactions 
[Ir(COD)OMe]2 
(mol%) ligand (mol%) Solvent 
temperature 
(°C) boron source 




(not specified) Hexane 60 
B2Pin2 
(1.5 equiv) 
no reaction / 
24 h 
dtbpy 
(not specified) Hexane 60 
HBPin 
(1.5 equiv) 
no reaction / 
24 h 
dtbpy 
(not specified) Heptane 80 
B2Pin2  
(1.5 equiv) 
no reaction / 
12 h 
dtbpy 
(not specified) Heptane 80 
HBPin 
(1.5 equiv) 
no reaction / 
12 h 
dtbpy 
(not specified) 1,4-dioxane 80 
B2Pin2  
(1.5 equiv) 
no reaction / 
12 h 
dtbpy 
(not specified) 1,4-dioxane 80 
HBPin 
(1.5 equiv) 
no reaction / 
12 h 
dtbpy 
(not specified) THF 80 
B2Pin2 
(1.5 equiv) 
no reaction / 
12 h 
phenanthroline 
(not specified) dry heptane 60 
HBPin 
(2.5 equiv) 
no reaction / 
24 h 
Me4-phen 
(not specified) dry heptane 60 
HBpin 
(2.5 equiv) < 20% / 24 h 
dtbpy 
(not specified) dry heptane 60 
HBPin 
(2.5 equiv) < 20% / 24 h 
Me4-phen (not 
specified) dry heptane 80 HBPin (3 equiv) > 50% / 24 h
dtbpy 
(not specified) dry heptane 80 HBPin (3 equiv) > 50% / 24 h
dtbpy 
(not specified) dry heptane 80 HBPin (4 equiv) 100% / 24 h 
(5 mol%) dtbpy 10 mol% dry heptane 65 
HBPin 
(4 equiv) 































Available via protection/SEAr/deprotection sequence,














(10 mol%) Me4-phen  30 mol% dry heptane 80 




/ 24 h 
(10 mol%) dtbpy 30 mol% dry heptane 80 
B2Pin2  
(4 equiv) 
100% C12 / 
24 h 
 
Where noted “not specified” for the amount of metal pre-catalyst and ligand in the Table S1, the exploratory 
experiments were run on 3-5 mg scale of substrate and the smallest amount of pre-catalyst and ligand that 
can be obtained on a tip of spatula (without weighing) was added. Use of B2Pin2 is advantageous since it is 
a solid easily handled. Thus, in reactions with B2pin2, all solids were balanced at once into the reaction vial, 
flushed with argon and solvent added last (also the case for C11 borylation below). In comparison, reactions 
with liquid HBPin gave identical results. C12 borylated MG was observed to undergo slow 




Compound 1: both procedures provide identical results 
General Procedure A: MG (25 mg, 62 µmol), [Ir(COD)OMe]2 (4 mg, 6.2 µmol), dtbpy (5 mg, 18.8 µmol) 
and B2Pin2 (64 mg, 250 µmol) were balanced into an oven dried vial. The vial was purged with argon, dry 
heptane (1 mL) was added under argon, and the vial was sealed with a Teflon-lined screw cap and heated 
to 80 °C. The reaction mixture (RM) became a dark-brown solution after 5–15 min of heating. After 24 h, 
when LR-MS and TLC (on alumina) indicated complete consumption of starting material (SM), the RM 
was concentrated to dryness. This crude intermediate was immediately used to prepare the –Cl 2 and –Br 3 
derivatives without further purification. 
 
General Procedure B: Catalyst [Ir(COD)OMe]2 (4 mg, 6.0 µmol) was dissolved in dry heptane (2.8 mL) in 
an oven dried vial under argon and HBPin (73 µL, 500 µmol), dtbpy (3.1 mg, 12 µmol) and MG (49 mg, 
120 µmol) were added consecutively under a stream of argon, with a 2 min stirring period at RT between 
each addition. The vial was sealed with a Teflon-lined screw cap and heated to 65 °C. RM was a dark red-
brown color. After 24 h, when LR-MS and TLC (on alumina) indicated complete consumption of SM, the 
RM was concentrated to dryness. This crude intermediate was immediately used to prepare the –Cl 2 and 






Compound 2 (12-Cl-MG). To the dark residue 1 (from Procedure A) was added CuCl2·H2O (37 mg, 217 
µmol) and a mixture of MeOH + H2O (2 + 0.5 mL). The vial was sealed and the RM was heated to 80 °C 
with vigorous stirring (slower stirring will cause incomplete conversion due to a precipitation of reactants 
during the reaction). After 12 h, TLC (EtOAc:Hex 1:1 + 2% Et3N) and LR-MS indicated complete 
conversion of the intermediate. Crude reaction mixture was adsorbed on silica and purified by column 
chromatography using EtOAc:Hex 1:9 + 5% Et3N. Product 2 was obtained as a yellow, amorphous solid 
(16 mg, 70% for 2 steps). 
1H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 7.44 (s, 1H), 6.97 (d, J = 8.3 Hz, 1H), 6.38 (d, J = 8.3 Hz, 1H), 
3.86 (s, 3H), 3.75 (s, 3H), 3.72 (s, 3H), 3.16 (dt, J = 11.8, 2.4 Hz, 1H), 3.13 – 2.99 (m, 3H), 2.97 – 2.88 (m, 
2H), 2.58 – 2.42 (m, 3H), 1.85 (dt, J = 13.0, 3.1 Hz, 1H), 1.82 – 1.72 (m, 1H), 1.67 – 1.59 (m, 1H), 1.25 – 
1.16 (m, 1H), 0.88 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.3, 160.7, 153.5, 134.6, 134.0, 
120.8, 118.9, 111.6, 109.4, 108.8, 100.7, 77.2, 61.7, 61.4, 57.9, 55.7, 53.7, 51.5, 40.8, 40.0, 30.0, 23.9, 19.3, 
13.0. LR-MS (APCI+) calcd. for C23H30ClN2O4+ [M+H]+: 433.2, found 433.3. 
 
 
Compound 3 (12-Br-MG). To the dark residue 1 (from Procedure B) was added CuBr2 (41 mg, 186 µmol) 
and a mixture of MeOH + H2O (2 + 0.5 mL). The vial was sealed and the RM was heated to 80 °C with 
vigorous stirring (slower stirring will cause incomplete conversion due to a precipitation of reactants during 
the reaction). After 12 h, TLC (EtOAc:Hex 1:1 + 2% Et3N) and LR-MS indicated complete conversion of 
the intermediate. Crude reaction mixture was adsorbed on silica and purified by column chromatography 
using EtOAc:Hex 1:9 + 5% Et3N. Product 3 was obtained as an amorphous, pale-yellow solid (21 mg, 65% 
for 2 steps). 
1H NMR (500 MHz, CDCl3) δ 7.78 (s, 1H), 7.45 (s, 1H), 7.11 (d, J = 8.3 Hz, 1H), 6.36 (d, J = 8.3 Hz, 1H), 
3.85 (s, 3H), 3.75 (s, 3H), 3.71 (s, 3H), 3.16 (dd, J = 11.3, 2.5 Hz, 1H), 3.13 – 2.99 (m, 3H), 2.96 – 2.88 
(m, 2H), 2.57 – 2.43 (m, 3H), 1.85 (dt, J = 13.0, 3.2 Hz, 1H), 1.82 – 1.72 (m, 1H), 1.63 (dd, J = 8.8, 5.5 Hz, 
1H), 1.28 – 1.17 (m, 1H), 0.87 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.3, 160.7, 154.1, 
135.3, 134.5, 123.7, 118.8, 111.5, 109.6, 101.4, 96.2, 61.8, 61.4, 57.9, 55.7, 53.7, 51.5, 40.9, 40.0, 30.0, 





Compound 3 (12-Br-MG): Preparation using NBS. 
 
MG (35 mg, 88 µmol) and NBS (15 mg, 88 µmol) were taken in a vial and dissolved in CH2Cl2 (1 mL) 
under argon.3 The reaction mixture was cooled to 0 °C and TFA (0.20 mL, 11.4 µmol) was added. The 
reaction was continued for 2 h at 0 °C until LR-MS and TLC indicated complete consumption of SM. The 
reaction mixture was quenched with saturated aq. NaHCO3 and extracted with EtOAc (3 × 5 mL). 
Combined EtOAc extracts were dried over Na2SO4 and evaporated. The product was purified by PTLC 
using EtOAc:Hex 1:4 + 2% Et3N and obtained as an amorphous yellow powder (25 mg, 60%). 
Note: Reaction was repeated three times. Out of three repeats, two gave only 12-Br-MG 3 and once we 
obtained a minor amount of 10-Br-MG (C12 : C10 = 19:5). 
The spectral properties of the product were identical to material obtained through the borylation procedure. 
 
Supplementary Figure 2: General strategy for C11 derivatization 
 
As the iridium-catalyzed borylation reactions are typically sterically controlled, one potential strategy to 
access the C11 position was to install a PG on the indole nitrogen to shield the C12 position . 
Accordingly, we attempted the Ir-catalyzed borylation reaction on MG bearing both electron-donating and 
electron-withdrawing protecting groups. 

























































































Boc-MG: MG (200 mg, 0.502 mmol) was dissolved in dry DCM (5 mL) and Boc2O (120 mg, 0.552 mmol) 
followed by DMAP (6 mg, 0.0502 mmol) were added in one portion. The mixture was stirred for 12 h at 
RT and directly poured on column for separation (EtOAc:Hex 1:5 + 5% Et3N; Rf = 0.48). The pure product 
(190 mg, 76%) was obtained as a yellowish, foamy solid. 
1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 0.7 Hz, 1H), 7.41 (s, 1H), 7.16 (t, J = 8.2 Hz, 1H), 6.65 (dd, J = 
8.1, 0.7 Hz, 1H), 3.89 (s, 3H), 3.72 (s, 3H), 3.71 (s, 3H), 3.65 – 3.52 (m, 1H), 3.13 (dt, J = 13.2, 3.5 Hz, 
1H), 3.06 (dd, J = 12.0, 2.1 Hz, 2H), 2.96 – 2.84 (m, 2H), 2.76 – 2.61 (m, 2H), 2.33 – 2.16 (m, 1H), 1.98 
(dt, J = 13.0, 2.4 Hz, 1H), 1.83 – 1.71 (m, 1H), 1.62 (s, 9H), 1.59 (d, J = 3.9 Hz, 1H), 1.25 – 1.21 (m, 1H), 
0.89 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.6, 160.8, 154.3, 150.9, 139, 135.5, 124.6, 119.2, 
116.9, 111.9, 108.6, 103.8, 83.8, 62.9, 61.8, 58.0, 55.7, 51.59, 51.57, 41.0, 40.8, 31.5, 28.5, 25.7, 20.0, 13.6. 
LR-MS (APCI+) calcd. for C28H39N2O6+ [M+H]+: 499.3, found 499.4. 
 
Supplementary Figure 4: In situ C11 borylation of Boc-MG and subsequent chlorination step 
 
 
When attempting chlorination of the crude material obtained by borylation of Boc-MG, a mixture of two 
products, MG and 11-Cl-MG (one spot on TLC) was obtained after column chromatography. We observed 
significant protodeborylation as well as boc-deprotection under the reaction conditions. Preliminary 
exploration showed that the halogenation step was strongly concentration and temperature dependent. This 
process was not further optimized as another protected MG derivative, mitragynine-ethylene glycol adduct 
MG-EG (4), was found to be a superior substrate for C11-borylation compared to Boc-MG.  
 
 
Dihydromitragynine (DHM): MG (100 mg, 251 µmol) was dissolved in neat TFA (1.5 mL). To the 
solution NaBH4 (37.9 mg, 1.00 mmol) was added and made to dissolve. The vial was left open for some 
time to let the H2 gas formed during the reaction to let off and then the reaction was made to continue 




































MeOH / H2O (4:1)











quenched with 1M NaOH solution and extracted with CH2Cl2 (3 × 25 mL). The combined extract was 
washed with brine, dried over MgSO4, and evaporated. The product was purified by PTLC using 
EtOAc:Hex 1:4 + 2% Et3N. DHM was obtained as a yellow solid (50 mg, 50%). 
1H NMR (500 MHz, CDCl3) δ 7.41 (s, 1H), 6.96 (t, J = 8.0 Hz, 1H), 6.37 (d, J = 7.7 Hz, 1H), 6.29 (dd, J = 
8.2, 0.6 Hz, 1H), 3.79 (d, J = 1.2 Hz, 6H), 3.69 (s, 3H), 3.52 (dd, J = 6.6, 3.2 Hz, 1H), 3.05 (dt, J = 12.4, 
6.4 Hz, 1H), 3.00 – 2.82 (m, 2H), 2.69 (dt, J = 11.6, 3.3 Hz, 1H), 2.54 (td, J = 13.0, 11.4 Hz, 1H), 2.19 – 
2.07 (m, 1H), 2.00 (dt, J = 11.6, 2.6 Hz, 1H), 1.96 – 1.75 (m, 4H), 1.62 – 1.48 (m, 2H), 1.44 – 1.34 (m, 
1H), 1.29 – 1.11 (m, 1H), 0.84 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.5, 160.7, 156.0, 
152.1, 128.4, 121.6, 112.1, 104.8, 102.1, 64.9, 64.7, 61.9, 59.1, 55.5, 55.0, 51.6, 41.1, 40.7, 37.9, 29.6, 27.9, 
19.5, 13.4. LR-MS (APCI+) calcd. for C23H33N2O4 [M+H]+: 401.2, found 401.4. 
 
Supplementary Figure 5: Borylation of MG analogs with oxidized (7OH), reduced (DHM), rearranged 




A/ 7OH was synthesized from MG as described in general procedure E.4 7OH (25 mg, 60 µmol), 
[Ir(COD)OMe]2 (5 mol%), ligand (dtbpyl or Me4-phen) (15 mol%) and B2Pin2 (4 equiv) was balanced into 
an oven dried vial. The vial was purged with argon, dry heptane (1 mL) was added under argon, and the 
vial was sealed with a Teflon-lined screw cap and heated to 65 °C. The reaction was heated for 24 h and 





























































B/ DHM (25 mg, 62 µmol), [Ir(COD)OMe]2 (5 mol%), ligand (dtbpyl or Me4-phen) (15 mol%) and B2Pin2 
(4 equiv) was balanced into an oven dried vial. The vial was purged with argon, dry heptane (1 mL) was 
added under argon, and the vial was sealed with a Teflon-lined screw cap and heated to 65 °C. The reaction 
was heated for 24 h and then was concentrated in vacuo. 1H-NMR of the crude material showed a partial 
conversion (50% conversion) to the C11-borylated product along with unreacted SM. To the crude dark 
residue of intermediate was added CuBr2 (4 equiv) and a mixture of MeOH (2.4 mL) + H2O (0.6 mL) (4:1). 
The vial was sealed, and the RM was then heated to 80 °C with vigorous stirring. After 24 h a complex and 
inseparable mixture of MG and DHM as the major products (~ 60% by 1H NMR), and 11-Br-mitragynine 
and 11-Br-2,3-dihydromitragynine as the minor products (~ 30% by 1H NMR) was formed. 
 
C/ MP was synthesized according to published procedure.5 MP (25 mg, 60 µmol), [Ir(COD)OMe]2 (5 
mol%), ligand (dtbpyl or Me4-phen ) (15 mol%) and B2Pin2 (4 equiv) were balanced into an oven dried vial. 
The vial was purged with argon, dry heptane (1 mL) was added under argon, and the vial was sealed with 
a Teflon-lined screw cap and heated to 65 °C. The reaction was heated for 24 h and then was concentrated 
in vacuo. Complete conversion of SM to C12-borylated product was determined through LR-MS and 1H-
NMR. To the resulting dark residue of intermediate was added CuBr2 (4 equiv) and a mixture of MeOH (2 
mL) + H2O (0.5 mL) (4:1). The vial was sealed, and the RM was then heated to 80 °C with vigorous stirring 




Compound 4 (MG-EG). Reaction was performed according to a published procedure.2 To a solution of 
MG (600 mg, 1.51 mmol) in dry MeCN (12 mL) were added dry ethylene glycol (12 mL) and PIFA (649 
mg, 1.51 mmol) at 0 °C and the RM was stirred for 1 h at 0 °C under argon atmosphere. After adding chilled 
saturated aqueous NaHCO3 solution (120 mL), the mixture was extracted with CH2Cl2 (3 × 40 mL). The 
combined extract was washed with brine, dried over MgSO4, and evaporated. The product was purified by 
column chromatography using 1:9 to 2:8 EtOAc:Hex + 2% Et3N gradient. Product 4 was obtained as a light 
green solid (485 mg, 70%) (The green color is due to the residual chlorophyll in the batch of MG extracted 
from the plant material). 
MG-EG crystals were grown by dissolving 4 in hot MeOH and allowing it to slowly cool to 




suitable for an X-ray crystallography. The absolute stereochemistry was assigned based on literature.6,7 X-








Supplementary Figure 6. ORTEP representation of the X-ray crystal structure of MG-EG (4) 
 
1H NMR (400 MHz, CDCl3) δ 7.41 (s, 1H), 7.07 (dd, J = 8.3, 7.7 Hz, 1H), 6.43 – 6.26 (m, 2H), 4.25 (s, 
1H), 3.92 (td, J = 11.6, 2.7 Hz, 1H), 3.86 – 3.81 (m, 4H, signal overlap), 3.78 (s, 3H), 3.70 (s, 3H), 3.67 
(dd, J = 11.3, 2.3 Hz, 1H), 3.46 – 3.38 (m, 1H), 2.98 (dd, J = 11.6, 2.2 Hz, 1H), 2.92 (dt, J = 13.0, 3.6 Hz, 
1H), 2.53 – 2.42 (m, 2H), 2.39 – 2.30 (m, 2H), 2.28 – 2.23 (m, 1H), 2.15 (dt, J = 14.4, 2.5 Hz, 1H), 1.87 – 
1.69 (m, 3H), 1.56 (d, J = 11.1 Hz, 1H), 1.24 – 1.21 (m, 1H), 0.84 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 169.2, 160.6, 157.1, 149.1, 130.0, 115.9, 111.9, 105.4, 102.9, 90.9, 81.5, 62.5, 61.8, 61.4, 61.0, 
58.7, 55.5, 51.4, 50.4, 40.6, 40.3, 35.6, 24.3, 19.3, 13.2. LR-MS (APCI+) calcd. for C25H35N2O6+ [M+H]+: 





General procedure: Compound 4 (30 mg, 65 µmol), [Ir(COD)OMe]2 (5 mol%), ligand (15 mol%) and 
B2Pin2 (4 equiv) were balanced into an oven dried vial. The vial was purged with argon, dry heptane (1 mL) 
was added under argon, and the vial was sealed with a Teflon-lined screw cap and heated to 65 °C. The 
reaction was heated for 15–24 h and then was concentrated in vacuo. To the resulting dark residue of 
intermediate was added CuBr2 (4 equiv) and a mixture of MeOH (2.4 mL) + H2O (0.6 mL) (4:1). The vial 
was sealed, and the RM was then heated to 80 °C with vigorous stirring. After 12 h, brine (10 ml) was 
added and the mixture was extracted with DCM (3 × 5 mL). The combined DCM extracts were dried over 











































was developed twice to improve resolution). After PTLC, the product was obtained as an inseparable 
mixture of 5 and 6 and the ratio was analyzed by 1H-NMR (see Supplementary Table 2) 
Supplementary Table 2. Ligand screening of MG-EG (4) borylation/bromination for product 
distribution 





















C-H borylation reaction (selectivity C11:C12 = 1.3-1.1:1) of 4 and subsequent bromination [Entry 3, 
Supporting Table 2] 
Starting material 4 (25 mg, 55 µmol), [Ir(COD)OMe]2 (1.8 mg, 2.7 µmol), dtbpy (2.2 mg, 8.1 µmol) and 
B2Pin2 (55 mg, 0.22 mmol) were balanced into an oven dried vial. The vial was purged with argon, dry 
heptane (1 mL) was added under argon, and the vial was sealed with a Teflon lined screw cap and heated 
to 65 °C. The RM became a dark brown solution after 5–15 minutes of heating. After 15–24 h, when LR-
MS indicated complete consumption of SM, the RM was concentrated to dryness. This intermediate was 
immediately used for further transformation. 
 
  
To the dark residue of borylated intermediate was added CuBr2 (37 mg, 0.17 mmol) and a mixture of MeOH 




(slower stirring will cause incomplete conversion due to a precipitation of reactants during the reaction). 
After 15 h, TLC (EtOAc:Hex 1:1 + 2% Et3N) and LR-MS indicated complete conversion of the 
intermediate. The RM was diluted with brine (15 mL) and extracted with DCM (3 × 5 mL). The combined 
DCM extracts were dried over Na2SO4 and evaporated. The product was purified by PTLC using 
EtOAc:Hex 1:4 + 2% Et3N (the plate was developed twice to improve resolution). Products 5 and 6 were 
obtained as a mixture (C11:C12 - 1.3-1.1:1) in the form of a pale-yellow solid (20-24 mg, 60-83%). 
 
C-H borylation reaction (selectivity C11:C12 = 16-20:1) of 4 and subsequent transformations 
General procedure C: Compound 4 (50 mg, 0.11 mmol), [Ir(COD)OMe]2 (3.6 mg, 5.5 µmol), Me4-phen 
(3.9 mg, 16 µmol) and B2Pin2 (111 mg, 0.44 mmol) were balanced into an oven dried vial. The vial was 
purged with argon, dry heptane (2.5 mL) was added under argon, and the vial was sealed with a Teflon-
lined screw cap and heated to 65 °C. The RM became a dark red-brown solution after 5–15 minutes of 
heating. After 17–24 h, when LR-MS indicated complete consumption of SM, the RM was concentrated to 
give the crude boronate ester. This intermediate was immediately used to prepare the -Cl (13), -Br (5), and 
-OH (14) derivatives without further purification. 
Up to 100 mg of 4 can be used in one reaction vial (8 mL volume) to prepare the boronate ester intermediate 
using only 1.5 mL of dry heptane. It is however necessary to divide the crude intermediate into multiple 
reaction vessels for the subsequent reaction (the reactions are very sensitive to the ratio of MeOH/H2O and 
total reaction volume). The intermediate boronate ester is air and moisture sensitive and unstable during a 
silica gel column purification. Other solvents than those used for further reactions (mainly chlorinated, e.g. 
DCM and CHCl3) can lead to a significant protodeborylation. Compounds prepared from the boronate ester 
intermediate are sometimes contaminated with decomposition products from excess of B2Pin2 (like 
pinacol). These can be removed either by repeated chromatography purification (preferably PTLC) or after 
further reaction steps. 
 
 
Compound 5 (11-Br-MG-EG). The boronate ester intermediate was prepared from 4 (50 mg, 0.11 mmol) 
as described in the general procedure C. To the dark residue of borylated intermediate was added CuBr2 (73 
mg, 0.33 mmol) and a mixture of MeOH + H2O (4 + 1 mL). The vial was sealed and the RM was then 
heated to 80 °C with vigorous stirring (slower stirring will cause incomplete conversion due to precipitation 
of reactants during the reaction). After 15 h, TLC (EtOAc:Hex 1:1 + 2% Et3N) and LR-MS indicated 




× 10 mL), and the combined DCM extracts were dried over Na2SO4 and evaporated. The product was 
purified by PTLC using EtOAc:Hex 1:4 + 2% Et3N (the plate was developed twice to improve resolution). 
Product 5 (along with 3-5% of inseparable C12 isomer) was obtained as a pale-yellow solid (35 mg, 60%). 
1H NMR (400 MHz, CDCl3) δ 7.40 (s, 1H), 6.54 (s, 2H), 4.29 (s, 1H), 3.91 (td, J = 11.6, 2.8 Hz, 1H), 3.82 
(s, 3H), 3.82 – 3.74 (m, 4H), 3.70 (s, 3H), 3.66 (dd, J = 11.6, 2.7 Hz, 1H), 3.41 (dd, J = 11.6, 2.5 Hz, 1H), 
2.98 (dd, J = 11.5, 2.2 Hz, 1H), 2.91 (dt, J = 13.0, 3.5 Hz, 1H), 2.49 – 2.40 (m, 2H), 2.38 – 2.29 (m, 2H), 
2.29 – 2.22 (m, 1H), 2.13 (dd, J = 14.4, 2.5 Hz, 1H), 1.83 – 1.69 (m, 3H), 1.56 (d, J = 15.0 Hz, 1H), 1.24 – 
1.21 (m, 1H), 0.84 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.2, 160.5, 157.3, 150.0, 122.8, 
115.0, 111.7, 108.7, 106.7, 91.0, 81.1, 62.5, 61.8, 61.3, 60.9, 58.6, 55.7, 51.4, 50.2, 40.6, 40.2, 35.4, 24.2, 
19.3, 13.2. HRMS (ESI+) calcd. for C25H34BrN2O6+ [M+H]+: 539.1584, found 539.1592 
 
 
Compound 14a (11-OTf-MG-EG). To a solution of 14 (115 mg, 0.24 mmol) in dry DMF (3 mL) at RT 
was added DIPEA (2 mL, 1.2 mmol) and N-phenyl-bis(trifluoromethanesulfonimide) (173 mg, 0.48 mmol). 
After the RM was stirred at 50 °C overnight, it was quenched by the addition of saturated aqueous NaHCO3 
and extracted with DCM (3 × 15 mL). The combined organic phases were washed with brine, dried over 
Na2SO4 and evaporated. The product was purified by column chromatography using EtOAc:Hex 3:7 + 2% 
Et3N. Product 14a was obtained as a yellow powder (101 mg, 70%).  
1H NMR (400 MHz, CDCl3) δ 7.41 (s, 1H), 6.28 (d, J = 3.8 Hz, 2H), 4.46 (s, 1H),  3.92 (td, J = 11.7, 3.1 
Hz, 1H), 3.84 (s, 3H), 3.82 – 3.74 (m, 4H), 3.73 – 3.65 (m, 4H), 3.43 (dd, J = 11.7, 2.5 Hz, 1H), 2.99 (dd, 
J = 11.5, 2.1 Hz, 1H), 2.92 (dt, J = 13.1, 3.6 Hz, 1H), 2.51 – 2.40 (m, 2H), 2.38 – 2.22 (m, 3H), 2.14 (dt, J 
= 14.4, 2.5 Hz, 1H), 1.81 – 1.74 (m, 2H), 1.74 – 1.64 (m, 1H), 1.57 (d, J = 11.2 Hz, 1H), 1.22 – 1.15 (m, 
1H), 0.85 (t, J = 7.4 Hz, 3H). 19F NMR (471 MHz, CDCl3) δ -72.03. 13C NMR (126 MHz, CDCl3) δ 169.2, 
160.6, 157.3, 150.8, 149.9, 122.8, 120.1, 117.5, 115.8, 115.0, 111.6, 98.6, 96.8, 91.1, 81.0, 62.6, 61.8, 61.3, 
60.8, 58.6, 55.9, 51.4, 50.2, 40.5, 40.1, 35.4, 24.3, 19.3, 13.2. LR-MS (APCI+) calcd. for C26H34F3N2O9S+ 
[M+H]+: 607.2, found 607.9. 
 
 
Compound 14b (11-Bu3Sn-MG-EG) 




To a solution of 5 (75 mg, 0.14 mmol) in dry dioxane (0.7 mL) at RT was added lithium chloride (30 mg, 
0.70 mmol), Pd(PPh3)4 (24.3 mg, 0.021 mmol, 10 mol%) and bis(tributyltin) (350 μL, 0.70 mmol). After 
stirring for 24 h at 100 °C, the RM was cooled to RT and concentrated in vacuo. The residue was dissolved 
in hexanes and then filtered through a pad of celite. After washing the filter cake several times with hexanes, 
the combined washings were evaporated. The product was purified by column chromatography using Hex 
+ 5% Et3N. The intermediate 14b was obtained as a yellow liquid (63 mg, 60%). 
 
Synthesis from Triflate 14a: To a solution of 14a (85 mg, 0.14 mmol) in dry dioxane (0.7 mL) at RT was 
added lithium chloride (30 mg, 0.70 mmol), Pd(PPh3)4 (24.3 mg, 0.021 mmol, 10 mol%) and bis(tributyltin) 
(350 μL, 0.70 mmol). After stirring for 24 h at 100 °C, the reaction mixture was cooled to RT and 
concentrated in vacuo. The residue was dissolved in hexanes and then filtered through a pad of celite. After 
washing the filter cake several times with hexanes, the combined washings were evaporated. The product 
was purified by column chromatography using Hex + 5% Et3N. The arylstannane intermediate 14b was 
obtained as a yellow liquid (74 mg, 70%). 
1H NMR (500 MHz, CDCl3) δ 7.44 (s, 1H), 6.80 – 5.74 (m, 2H), 4.23 (s, 1H), 3.95 (td, J = 11.6, 2.5 Hz, 
1H), 3.87 (s, 4H), 3.81 (s, 3H), 3.72 (s, 3H), 3.69 (dd, J = 11.4, 2.3 Hz, 1H), 3.45 (dd, J = 11.4, 2.3 Hz, 
1H), 3.01 (dd, J = 11.6, 2.1 Hz, 1H), 2.94 (dt, J = 13.1, 3.6 Hz, 1H), 2.54 – 2.44 (m, 2H), 2.43 – 2.33 (m, 
2H), 2.28 (dd, J = 11.3, 3.3 Hz, 1H), 2.16 (dt, J = 14.4, 2.4 Hz, 1H), 1.91 – 1.74 (m, 3H), 1.61 – 1.48 (m, 
6H), 1.35 (h, J = 7.3 Hz, 6H), 1.25 – 1.19 (m, 1H), 1.14 – 0.99 (m, 7H), 0.92 (t, J = 7.3 Hz, 9H), 0.86 (t, J 
= 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.2, 160.4, 156.3, 148.4, 143.9, 115.9, 113.0, 111.7, 109.9, 
90.8, 81.5, 62.4, 61.7, 61.27, 60.9, 58.5, 55.2, 51.3, 50.3, 40.5, 40.2, 35.5, 29.1, 27.4, 24.2, 19.2, 13.7, 13.1, 
9.7. LR-MS (APCI+) calcd. for C37H61N2O6Sn




Compound 7 (11-F-MG-EG). To a solution of 14b (81 mg, 0.11 mmol) in dry acetone (2.0 mL) at RT was 
added silver triflate (56 mg, 0.22 mmol) and freshly prepared 1-chloromethyl-4-fluoro-1,4-
diazoniabicyclo[2.2.2]octane bis(hexafluorophosphate8 (54 mg, 0.165 mmol). The RM was stirred for 20 
min at RT and then concentrated in vacuo. Residue was dissolved in DCM and a few drops of 1N HCl 
solution was added to the solution mixture and then extracted with DCM, dried over Na2SO4 and the 




product, which can be purified by PTLC using EtOAc:Hex 1:4 + 2% Et3N by developing the plate multiple 
times. Product 7 was obtained as a white solid (31 mg, 60%).  
1H NMR (400 MHz, CDCl3) δ 7.40 (s, 1H), 6.39 – 5.84 (m, 2H), 4.31 (s, 1H), 3.91 (td, J = 11.7, 2.7 Hz, 
1H), 3.84 – 3.75 (m, 7H), 3.70 (s, 3H), 3.66 (dd, J = 11.5, 2.5 Hz, 1H), 3.42 (dd, J = 11.6, 2.4 Hz, 1H), 3.02 
– 2.93 (m, 1H), 2.91 (dt, J = 13.0, 3.6 Hz, 1H), 2.44 (d, J = 11.6 Hz, 2H), 2.40 – 2.19 (m, 3H), 2.19 – 2.05 
(m, 1H), 1.90 – 1.64 (m, 3H), 1.58 (s, 1H), 1.26 (s, 1H), 0.84 (t, J = 7.4 Hz, 3H). 13C NMR (fluorine 
decoupled) (126 MHz, CDCl3) δ 169.2, 164.8, 160.6, 157.6, 149.8, 111.8, 111.3, 93.0, 91.2, 91.2, 80.9, 
62.4, 61.8, 61.4, 60.9, 58.7, 55.7, 51.4, 50.4, 40.6, 40.2, 35.7, 24.3, 19.3, 13.2. 19F (proton decoupled) NMR 
(376 MHz, CDCl3) δ -110.19. HRMS (ESI+) calcd. for C25H34FN2O6+ [M+H]+: 477.2401, found 477.2405. 
 
 
Compound 8 (11-I-MG-EG). Compound 5 (20.0 mg, 37.2 µmol), dried NaI (15.6 mg, 0.1 mmol), CuI (0.5 
mg, 2.6 µmol) and N,N′-dimethylethylenediamine (2.3 mg, 26 µmol) were balanced into an oven-dried vial. 
The vial was purged with argon and dry 1,4-dioxane (0.25 mL) was added under a stream of argon. The 
RM was heated to 110 °C for 24 h. LR-MS indicated formation of product but with a low conversion (TLC 
is not indicative enough due to a low difference in Rf value of starting compound and product). The RM 
was evaporated and dried under high vacuum. More NaI (63.7 mg, 0.42 mmol), CuI (3 mg, 16 µmol) and 
N,N′-dimethylethylenediamine (9.4 mg, 11 µmol) were added followed by dry 1,4-dioxane (0.3 mL) under 
Ar. The RM was heated for 22 h, after which LR-MS indicated nearly total conversion. The RM was diluted 
with DCM (10 mL) and washed 3× with diluted aq. NH3 (H2O:28% aq. NH3 10:0.1 mL), DCM was dried 
over Na2SO4 and evaporated. The crude product was filtered through silica gel in EtOAc:Hex 1:1 + 2% 
Et3N and further purified by PTLC (EtOAc:Hex 1:4 + 2% Et3N, 2× developed). Product 8 was obtained as 
a yellow solid (13 mg, 59%). 
1H NMR (500 MHz, CDCl3) δ 7.40 (s, 1H), 6.72 (d, J = 10.7 Hz, 2H), 4.28 (s, 1H), 3.91 (td, J = 11.8, 2.9 
Hz, 1H), 3.85 – 3.80 (m, 3H), 3.80 – 3.74 (m, 4H), 3.72 – 3.63 (m, 4H), 3.47 – 3.37 (m, 1H), 3.03 – 2.94 
(m, 1H), 2.90 (dt, J = 13.2, 3.6 Hz, 1H), 2.51 – 2.39 (m, 2H), 2.38 – 2.29 (m, 2H), 2.28 – 2.21 (m, 1H), 
2.11 (dt, J = 14.5, 2.6 Hz, 1H), 1.84 – 1.66 (m, 3H), 1.55 (d, J = 11.1 Hz, 1H), 1.24 – 1.16 (m, 1H), 0.84 (t, 
J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.2, 160.6, 157.4, 150.2, 116.0, 114.7, 112.7, 111.7, 
94.0, 90.9, 81.3, 62.5, 61.8, 61.3, 60.8, 58.6, 55.8, 51.4, 50.2, 40.6, 40.2, 35.4, 24.3, 19.3, 13.2. LR-MS 





Compound 9 (11-CH3-MG-EG). Compound 5 (30 mg, 56 µmol), Pd2(dba)3 (6 mg, 6.7 µmol), Xphos (4.4 
mg, 9.2 µmol), and bis(trimethylaluminum)-1,4-diazabicyclo[2.2.2]octane adduct (DABAL-Me3, 57 mg, 
0.22 mmol) were balanced into an oven dried vial. The vial was purged with argon, dry THF (1.5 mL) was 
added under argon, and the vial was sealed with a Teflon-lined screw cap and heated to 60 °C. After stirring 
for 2 h, complete conversion was observed by TLC-MS. The reaction mixture was cooled to RT and 
concentrated in vacuo. The product was purified by column chromatography using EtOAc:Hex 1:4 + 2% 
Et3N. Product 9 was obtained as a yellow solid (16 mg, 60%). 
1H NMR (500 MHz, CDCl3) δ 7.41 (s, 1H), 6.21 (d, J = 0.8 Hz, 2H), 4.17 (s, 1H), 3.91 (td, J = 11.6, 2.6 
Hz, 1H), 3.86 – 3.82 (m, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.69 (s, 3H), 3.65 (dd, J = 11.4, 2.4 Hz, 1H), 3.47 
– 3.33 (m, 1H), 2.98 (dd, J = 11.5, 2.1 Hz, 1H), 2.91 (dt, J = 13.1, 3.6 Hz, 1H), 2.45 (tt, J = 9.4, 2.9 Hz, 
2H), 2.40 – 2.28 (m, 2H), 2.27 (s, 3H), 2.24 – 2.19 (m, 1H), 2.13 (dt, J = 14.9, 2.8 Hz, 1H), 1.85 – 1.71 (m, 
3H), 1.55 (d, J = 11.3 Hz, 1H), 1.25 – 1.16 (m, 1H), 0.83 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ 169.2, 160.4, 156.7, 149.1, 140.3, 113.0, 111.7, 106.0, 103.8, 90.9, 81.2, 62.3, 61.6, 61.3, 60.9, 58.5, 55.2, 




Compound 10 (11-Ph-MG-EG). Compound 5 (20 mg, 37 µmol), phenylboronic acid (9.8 mg, 80 µmol), 
CsOAc (16.1 mg, 84 µmol, thoroughly dried under high vacuum while heating until melted) and 
Pd(dppf)Cl2∙CH2Cl2 (2.0 mg, 2.4 µmol) were balanced into an oven-dried vial. The vial was purged with 
argon, dry THF (0.3 mL) was added under a stream of argon, and the vial was closed with a Teflon-lined 
solid screw cap and heated to 70 °C. After 7 h, LR-MS and TLC indicated full consumption of starting 
material. The RM was diluted with brine (5 mL) and extracted with DCM (3 × 5 mL). The combined DCM 
extracts were dried over Na2SO4, evaporated, and the crude residue was purified by PTLC (EtOAc:Hex 1:4 
+ 2% Et3N and Et2O + 1% Et3N). Product 10 was obtained as a pale-yellow solid (16 mg, 81%). 
1H NMR (400 MHz, CDCl3) δ 7.57 – 7.50 (m, 2H), 7.44 – 7.37 (m, 3H), 7.35 – 7.29 (m, 1H), 6.62 – 6.56 
(m, 2H), 4.33 (s, 1H), 3.98 – 3.81 (m, 5H), 3.79 (s, 3H), 3.70 (s, 4H), 3.49 – 3.42 (m, 1H), 3.00 (dd, J = 
11.5, 2.1 Hz, 1H), 2.93 (dt, J = 13.0, 3.6 Hz, 1H), 2.56 – 2.43 (m, 2H), 2.43 – 2.32 (m, 2H), 2.32 – 2.23 (m, 




0.85 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.3, 160.6, 157.1, 149.5, 143.9, 142.0, 128.7, 
127.3, 115.1, 111.8, 104.5, 102.6, 91.1, 81.4, 62.6, 61.8, 61.4, 61.0, 58.6, 55.5, 51.4, 50.4, 40.6, 40.3, 35.7, 
24.3, 19.3, 13.2. Overlap between carbon signals for phenyl CH and acrylic CH. LR-MS (APCI+) calcd. 
for C31H39N2O6+ [M+H]+: 535.3, found 536.0. 
 
 
Compound 11 (11-CONH2-MG-EG) 
Synthesis from Bromide 5. Compound 5 (20.0 mg, 37 µmol), Pd(OAc)2 (0.5 mg, 2.2 µmol), dppf (2.6 mg, 
4.7 µmol), imidazole (2.6 mg, 38 µmol), Co2(CO)8 (7.6 mg, 22 µmol) and NH4Cl (8.0 mg, 0.15 mmol) were 
balanced into an oven-dried vial. The vial was purged with argon and dry 1,4-dioxane (0.8 mL) was added 
followed by DIPEA (26 µL, 0.15 mmol) under a stream of argon. The vial was sealed with a Teflon-lined 
screw cap and the RM was heated to 90 °C. After 15 h, TLC (EtOAc:Hex 1:1 + 2% Et3N) indicated only 
partial conversion, so additional Co2(CO)8 (8.0 mg, 23 µmol), NH4Cl (8.0 mg, 0.15 mmol) and DIPEA (26 
µL, 0.15 mmol) were added. Heating was continued for another 24 h (no further conversion was observed). 
The RM was diluted with MeOH and adsorbed on celite. The compound was purified by column 
chromatography with a gradient of EtOAc:Hex 1:1 + 2% Et3N with 5 to 10% MeOH. The product was 
further purified on PTLC in acetone:Hex 1:1 + 2% Et3N and coeluting Et3N salts were removed by washing 
of its CHCl3 solution with 2M Na2CO3. Product 11 was obtained as a pale-yellow solid (6.5 mg, 35%). 
 
Synthesis from Triflate 14a. Compound 14a (25 mg, 41 µmol), Pd(OAc)2 (0.8 mg, 3.6 µmol), dppf (2.7 
mg, 4.9 µmol), imidazole (0.9 mg, 13 µmol), Co2(CO)8 (9.7 mg, 28 µmol) and NH4Cl (9.3 mg, 0.17 mmol) 
were balanced into an oven-dried vial. The vial was purged with argon and dry 1,4-dioxane (0.9 mL) was 
added followed by DIPEA (30 µL, 0.17 mmol) under a stream of argon. The vial was sealed with a Teflon-
lined screw cap and the RM was heated to 90 °C. After 21.5 h, TLC (EtOAc:Hex 1:1 + 2% Et3N) indicated 
full conversion, so the RM was diluted with MeOH and adsorbed on celite. The product was partially 
separated by column chromatography in EtOAc + 2% Et3N to acetone + 2% Et3N (compound spread and 
did not separate very well). Product was further purified on PTLC in EtOAc:acetone 2:1 + 2% Et3N 
(developed 2× to improve resolution). Finally, the compound was eluted from SiO2 with acetone (no Et3N) 
to remove Et3N salts. Product 11 was obtained as a pale-yellow solid (11.7 mg, 57%). 
1H NMR (500 MHz, CDCl3) δ 7.39 (s, 1H), 6.93 (s, 1H), 6.65 (s, 1H), 5.97 (s, 1H), 5.73 (s, 1H), 4.44 (s, 
1H), 3.98 – 3.84 (m, 4H), 3.79 (s, 4H), 3.70 (s, 4H), 3.43 (dd, J = 11.8, 2.5 Hz, 1H), 3.05 – 2.95 (m, 1H), 
2.91 (dt, J = 13.1, 3.6 Hz, 1H), 2.47 (t, J = 9.9 Hz, 2H), 2.35 (td, J = 12.0, 5.3 Hz, 2H), 2.26 (dd, J = 11.9, 




(t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.7, 169.2, 160.6, 157.2, 149.3, 135.7, 120.1, 111.8, 
103.7, 103.3, 91.2, 81.3, 62.7, 61.8, 61.4, 60.8, 58.6, 55.8, 51.4, 50.2, 40.6, 40.2, 35.3, 24.3, 19.3, 13.2 LR-
MS (APCI+) calcd. for C26H36N3O7+ [M+H]+: 502.3, found 502.6. 
 
 
Compound 12 (11-CN-MG-EG). Compound 5 (30 mg, 0.05 mmol), Pd2(dba)3 (30.5 mg, 0.033 mmol), Zn 
dust (5.4 mg, 0.08 mmol), Zn(CN)2 (11.5  mg, 0.09 mmol) and [HP(tBu)3]BF4 (19.1  mg, 0.06 mmol) were 
balanced into an oven-dried vial. The vial was purged with argon, dry DMF (1.6 mL) was added under a 
stream of argon, and the vial was closed with a Teflon-lined solid screw cap and reacted at RT for 1 h. After 
1 h, LR-MS and TLC indicated full consumption of starting material. The RM was diluted with brine (5 
mL) and extracted with EtOAc (3 × 5 mL). The combined EtOAc extracts were dried over Na2SO4, 
evaporated, and the crude residue was purified by PTLC (EtOAc:Hex 1:4 + 2% Et3N and Et2O + 1% Et3N). 
The product could not be purified as the free base and so was converted to its HCl salt. After the HCl salt 
was formed it was washed with hexane for several times to purify it. Product 12 was then obtained as the 
HCl salt as a pale-yellow solid (14 mg, 60%). 
1H NMR (400 MHz, CD3OD) (HCl salt of 12) δ 7.63 (s, 1H), 6.92 (d, J = 1.1 Hz, 1H), 6.79 (d, J = 1.1 Hz, 
1H), 3.98 – 3.94 (m, 1H), 3.92 (s, 3H), 3.90 (s, 3H), 3.79 – 3.76 (m, 2H), 3.73 (s, 3H), 3.64 – 3.49 (m, 2H), 
3.46 – 3.37 (m, 2H), 3.37 (s, 1H), 3.31 – 3.20 (m, 2H), 2.65 (dt, J = 14.8, 12.8 Hz, 1H), 2.41 (dt, J = 15.4, 
2.5 Hz, 1H), 2.14 (d, J = 14.8 Hz, 1H), 2.09 – 1.92 (m, 2H), 1.69 – 1.45 (m, 2H), 1.34 (t, J = 7.4 Hz, 1H), 
0.97 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CD3OD) δ 168.5, 161.9, 157.2, 149.6, 119.9, 118.5, 113.7, 
108.6, 108.5, 107.3, 88.8, 80.0, 62.4, 61.2, 60.6, 60.2, 56.1, 55.0, 50.5, 49.9, 39.1, 37.3, 32.2, 22.4, 17.7, 
11.3. LR-MS (APCI+) calcd. for C26H34N3O6+ [M+H]+: 484.3, found 484.6 
 
 
Compound 13 (11-Cl-MG-EG). The boronate ester intermediate was prepared from 4 (50 mg, 0.11 mmol) 
as described in the general procedure C. To the dark residue of intermediate was added CuCl2∙2H2O (53.0 
mg, 0.31 mmol) and a mixture of MeOH + H2O (4 + 1 mL). The vial was sealed, and the RM was then 
heated to 80 °C with vigorous stirring (slower stirring will cause incomplete conversion due to precipitation 
during the reaction). After 17 h, TLC (EtOAc:Hex 1:1 + 2% Et3N) and LR-MS indicated complete 
conversion of the intermediate. The RM was diluted with brine (15 mL) and extracted with DCM (3 × 10 




PTLC using EtOAc:Hex 1:4 + 2% Et3N (the plate was developed twice to improve resolution). Product 13 
was obtained as a white solid (32 mg, 60%). 
1H NMR (400 MHz, CDCl3) δ 7.41 (s, 1H), 6.38 (d, J = 2.7 Hz, 2H), 4.30 (s, 1H), 3.91 (dd, J = 13.0, 10.4 
Hz, 1H), 3.82 (s, 4H), 3.79 (s, 3H), 3.70 (s, 3H), 3.69 – 3.63 (m, 1H), 3.49 – 3.36 (m, 1H), 2.95 (dd, J = 
27.1, 12.1 Hz, 2H), 2.54 – 2.38 (m, 2H), 2.39 – 2.22 (m, 3H), 2.13 (d, J = 14.2 Hz, 1H), 1.86 – 1.72 (m, 
3H), 1.61 – 1.52 (m, 1H), 1.24 – 1.17 (m, 1H), 0.85 (t, J = 7.4 Hz, 3H).13C NMR (101 MHz, CDCl3) δ 
169.2, 160.6, 157.2, 149.8, 135.1, 114.6, 111.8, 105.9, 103.9, 91.1, 81.1, 62.49, 61.8, 61.4, 60.9, 58.6, 55.8, 




Compound 14 (11-OH-MG-EG). The boronate ester intermediate was prepared from 4 (50 mg, 0.11 mmol) 
as described in the general procedure C. The dark residue was dissolved in THF (0.7 mL) and 30% H2O2 
(102 µL, 0.66 mmol) was added dropwise over 5–7 min at 0 °C. The reaction mixture was then stirred for 
30 min at RT. The RM was then quenched with 5% Na2S2O3∙5H2O (1 ml) and extracted with DCM (3 × 10 
mL). The combined DCM extracts were dried over Na2SO4, evaporated, and the product was purified by 
PTLC using EtOAc:Hex 1:4 + 2% Et3N (the plate was developed twice to improve resolution). Product 14 
was obtained as a pale-brown solid (26 mg, 50%).  
1H NMR (400 MHz, CDCl3) δ 7.40 (s, 1H), 5.96 – 5.83 (m, 2H), 4.23 (s, 1H), 3.94 – 3.83 (m, 2H), 3.80 (s, 
3H), 3.78 (s, 3H), 3.70 (s, 3H), 3.64 (dd, J = 8.5, 2.3 Hz, 1H), 3.43 (d, J = 9.4 Hz, 1H), 3.00 (dd, J = 11.7, 
2.1 Hz, 1H), 2.92 (dt, J = 12.9, 3.6 Hz, 1H), 2.49 – 2.43 (m, 2H), 2.39 – 2.19 (m, 4H), 2.11 (dt, J = 14.4, 
2.5 Hz, 1H), 1.85 – 1.70 (m, 2H), 1.58 (d, J = 11.4 Hz, 1H), 1.31 (s, 1H), 0.85 (t, J = 7.3 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 169.2, 160.6, 158.4, 157.8, 149.6, 111.9, 108.0, 93.5, 91.5, 90.9, 81.1, 62.3, 61.9, 
61.5, 61.4, 58.6, 55.4, 51.4, 50.7, 40.7, 40.1, 35.9, 24.3, 19.4, 13.2. HRMS (ESI+) calcd. for C25H35N2O7+ 
[M+H]+: 475.2444, found 475.2437. 
 
 
Deprotection of MG-EG adduct derivatives 
General procedure D: Reactions were performed according to a published procedure.2  
Starting material (5, 7, or 13, 0.11 mmol) was dissolved in AcOH (2.0 mL) under argon and NaBH3CN 
(13.7 mg, 0.22 mmol) was added to the solution. After stirring at RT for 15 min, another portion of 
NaBH3CN (13.7 mg, 0.22 mmol) was added and stirring continued for 1 h. After this time, MeOH (81 µL) 




solution and extracted with DCM. After drying over Na2SO4, the DCM extract was evaporated. Product 
was purified by PTLC using an appropriate solvent mixture as described for each derivative. 
 
 
Compound 15 (11-F-MG). The reaction was performed according to the general procedure D except after 
addition of MeOH the RM was stirred for 1 h at 90 °C. The crude material was purified by PTLC using 
EtOAc:Hex 1:4 + 2% Et3N. Product 15 was obtained as a yellow solid (32 mg, 70%). 
1H NMR (500 MHz, CDCl3) δ 7.74 (s, 1H), 7.43 (s, 1H), 6.59 (dd, J = 9.3, 2.0 Hz, 1H), 6.26 (dd, J = 11.8, 
2.0 Hz, 1H), 3.84 (s, 3H), 3.73 (s, 3H), 3.70 (s, 3H), 3.18 – 2.97 (m, 4H), 2.96 – 2.83 (m, 2H), 2.62 – 2.36 
(m, 3H), 1.84 – 1.73 (m, 2H), 1.69 – 1.55 (m, 1H), 1.29 – 1.16 (m, 1H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 169.3, 161.1, 159.9 (d, J = 182.0 Hz), 154.7 (d, J = 12.4 Hz), 136.2 (d, J = 15.2 Hz), 
133.8 (d, J = 3.3 Hz), 114.1, 111.6, 108.0, 90.3 (d, J = 26.3 Hz), 90.2 (d, J = 28.7 Hz), 61.7, 61.3, 57.9, 
55.6, 53.8, 51.5, 40.8, 40.0, 30.1, 23.9, 19.2, 13.0. 19F (proton decoupled) NMR (376 MHz, CDCl3) δ -
119.25. HRMS (ESI+): calcd. for C23H30FN2O4+ [M+H]+: 417.2256, found 417.2248. 
 
 
Compound 16 (11-Cl-MG). The reaction was performed according to the general procedure D. The crude 
material was purified by PTLC using EtOAc:Hex 1:4 + 2% Et3N. Product 16 was obtained as a yellow solid 
(33 mg, 70%). 
1H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 7.42 (s, 1H), 6.89 (d, J = 1.6 Hz, 1H), 6.43 (d, J = 1.5 Hz, 1H), 
3.85 (s, 3H), 3.72 (s, 3H), 3.70 (s, 3H), 3.15 – 2.97 (m, 4H), 2.95 – 2.86 (m, 2H), 2.61 – 2.33 (m, 3H), 1.85 
– 1.70 (m, 2H), 1.66 – 1.57 (m, 1H), 1.32 – 1.16 (m, 1H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 169.3, 160.7, 154.6, 137.1, 134.3, 127.2, 116.5, 111.6, 108.2, 104.5, 101.4, 61.7, 61.3, 57.9, 55.6, 







Compound 17 (11-Br-MG). The reaction was performed according to the general procedure D. The crude 
material was purified by PTLC using EtOAc:Hex 1:4 + 2% Et3N. Product 17 was obtained as a yellow solid 
(42 mg, 80%). 
1H NMR (500 MHz, CDCl3) δ 7.77 (s, 1H), 7.43 (s, 1H), 7.05 (d, J = 1.4 Hz, 1H), 6.55 (d, J = 1.5 Hz, 1H), 
3.85 (s, 3H), 3.73 (s, 3H), 3.71 (s, 3H), 3.14 – 2.97 (m, 4H), 2.94 – 2.87 (m, 2H), 2.55 – 2.41 (m, 3H), 1.83 
– 1.71 (m, 2H), 1.62 (dd, J = 8.6, 5.3 Hz, 1H), 1.24 – 1.15 (m, 1H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 169.3, 160.7, 154.7, 137.5, 134.3, 116.8, 114.5, 111.5, 108.3, 107.4, 104.0, 61.7, 61.2, 57.9, 
55.7, 53.8, 51.5, 40.8, 40.0, 30.0, 23.9, 19.2, 13.0. LR-MS (APCI+) calcd. for C23H30BrN2O4+ [M+H]+: 
477.2, found 477.4. 
 
 
Compound 18 (11-CH3-MG). Compound 9 (22 mg, 0.046 mmol) was dissolved in AcOH (1.0 mL) under 
argon and NaBH3CN (4.4 mg, 0.069 mmol) was added to the solution. After stirring at RT for 15 min, 
another portion of NaBH3CN (4.4 mg, 0.069 mmol) was added and the stirring continued for 2 h at room 
temperature until TLC-MS showed complete consumption of SM. The RM was added into a cold 
concentrated NH4OH solution and extracted with DCM. After drying over Na2SO4, the DCM extract was 
evaporated. The crude material was purified by PTLC using EtOAc:Hex 1:4 + 2% Et3N. Product 18 was 
obtained as a yellow solid (11.3 mg, 60%). 
1H NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 7.43 (s, 1H), 6.69 (d, J = 1.0 Hz, 1H), 6.28 (d, J = 1.1 Hz, 1H), 
3.85 (s, 3H), 3.72 (s, 3H), 3.70 (s, 3H), 3.14 – 3.11 (m, 1H), 3.10 – 3.05 (m, 2H), 3.04 – 2.97 (m, 1H), 2.96 
– 2.86 (m, 2H), 2.56 – 2.41 (m, 3H), 2.40 (s, 3H), 1.83 – 1.72 (m, 2H), 1.60 – 1.58 (m, 1H), 0.88 – 0.84 (m, 
1H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.4, 160.6, 154.3, 137.7, 133.1, 131.95, 
115.7, 111.7, 107.8, 104.2, 101.8, 61.7, 61.4, 57.9, 55.4, 53.9, 51.5, 40.9, 40.1, 24.0, 22.2, 19.3, 13.0. LR-
MS (APCI+): calcd. for C24H33N2O4+ [M+H]+: 413.5, found 413.8. 
 
 
Compound 19 (11-Ph-MG). Compound 10 (64 mg, 0.12 mmol) was dissolved in AcOH (2.1 mL) under 
argon and NaBH3CN (14.6 mg, 0.23 mmol) was added to the solution. After stirring at RT for 1 h, MeOH 
(0.1 mL) was added and the RM was heated to 90 °C for 0.5 h. After cooling to RT, the RM was added into 




was evaporated. The crude material was purified by PTLC using EtOAc:Hex 1:4 + 2% Et3N. Product 19 
was obtained as a yellow solid (32 mg, 56%). 
1H NMR (500 MHz, CDCl3) δ 7.73 (s, 1H), 7.65 – 7.57 (m, 2H), 7.44 (s, 1H), 7.43 – 7.39 (m, 2H), 7.32 – 
7.27 (m, 1H), 7.12 (d, J = 1.2 Hz, 1H), 6.70 (d, J = 1.2 Hz, 1H), 3.94 (s, 3H), 3.74 (s, 3H), 3.71 (s, 3H), 
3.22 – 3.08 (m, 2H), 3.07 – 2.97 (m, 3H), 2.97 – 2.90 (m, 1H), 2.59 – 2.50 (m, 2H), 2.49 – 2.41 (m, 1H), 
1.87 – 1.74 (m, 1H), 1.69 – 1.58 (m, 2H), 1.22 (d, J = 12.0 Hz, 1H), 0.87 (t, J = 7.4 Hz, 3H).13C NMR (126 
MHz, CDCl3) δ 169.4, 160.7, 154.6, 143.0, 137.8, 135.8, 134.6, 128.7, 127.5, 126.6, 117.2, 111.7, 108.1, 
103.2, 100.1, 61.7, 61.5, 57.9, 55.6, 53.9, 51.5, 40.9, 40.1, 30.1, 24.0, 19.3, 13.0. LR-MS (APCI+): calcd. 
for C29H35N2O4+ [M+H]+: 475.6, found 475.8. 
 
 
Compound 20 (11-CONH2-MG). Compound 11 (37 mg, 74 µmol) was dissolved in AcOH (1.3 mL) under 
argon and NaBH3CN (9.4 mg, 0.15 mmol) was added to the solution. After stirring at RT for 15 min, another 
portion of NaBH3CN (9.4 mg, 0.15 mmol) was added and stirring continued for 1 h. MeOH (69 µL) was 
then added and the RM was heated to 90 °C for 2 h. After cooling to RT, the RM was added into a cold 
concentrated NH4OH solution and extracted with DCM. After drying over Na2SO4, the DCM extract was 
evaporated. The crude material was purified by repeated PTLC using DCM:MeOH 95:5 and 
EtOAc:Hex:MeOH 1:1:0.1 + 2% Et3N. Product 20 was obtained as an orange solid (11.4 mg, 35%). 
1H NMR (500 MHz, CDCl3) δ 8.54 (s, 1H), 7.41 – 7.36 (m, 2H), 6.89 (s, 1H), 6.14 (s, 1H), 5.90 (s, 1H), 
3.88 (s, 3H), 3.69 (d, J = 1.3 Hz, 6H), 3.08 (t, J = 13.7 Hz, 2H), 3.01 (td, J = 9.8, 2.9 Hz, 2H), 2.92 (td, J = 
13.8, 12.7, 4.5 Hz, 2H), 2.49 (dd, J = 14.5, 10.1 Hz, 2H), 2.46 – 2.38 (m, 1H), 1.89 (d, J = 12.8 Hz, 1H), 
1.80 – 1.70 (m, 1H), 1.64 – 1.57 (m, 1H), 1.23 – 1.14 (m, 1H), 0.85 (t, J = 7.3 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 171.1, 169.4, 160.8, 154.2, 137.3, 136.5, 126.7, 120.7, 111.5, 108.4, 105.0, 98.8, 61.7, 61.4, 
57.9, 55.6, 53.7, 51.5, 40.7, 39.9, 29.8, 23.8, 19.3, 13.0. LR-MS (APCI+): calcd. for C24H32N3O5+ [M+H]+: 
442.2, found 442.9. 
 
 
Compound 21 (11-CN-MG). Compound 12 (44 mg, 0.09 mmol) was dissolved in AcOH (0.8 mL) under 
argon and NaBH3CN (14.2 mg, 0.23 mmol) was added to the solution. After stirring at RT for 15 min, 




The RM was then added into a cold concentrated NH4OH solution and extracted with DCM. After drying 
over Na2SO4, the DCM extract was evaporated. The crude material was purified by PTLC using EtOAc:Hex 
1:4 + 2% Et3N. Product 21 was obtained as a yellow solid (13 mg, 34%). 
1H NMR (500 MHz, CDCl3) δ 8.16 (s, 1H), 7.43 (s, 1H), 7.27 (d, J = 1.2 Hz, 1H), 6.62 (d, J = 1.2 Hz, 1H), 
3.89 (s, 3H), 3.73 (s, 3H), 3.71 (s, 3H), 3.16 (dd, J = 11.5, 2.3 Hz, 1H), 3.11 – 2.99 (m, 3H), 2.97 – 2.88 
(m, 2H), 2.58 – 2.48 (m, 2H), 2.47 – 2.41 (m, 1H), 1.83 (dt, J = 12.8, 3.1 Hz, 1H), 1.79 – 1.69 (m, 1H), 
1.65 (s, 1H), 1.22 (td, J = 7.5, 6.4, 2.8 Hz, 1H), 0.87 (t, J = 7.3 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 
169.3, 160.8, 154.4, 138.0, 135.9, 121.3, 121.3, 111.4, 110.1, 109.3, 103.6, 102.2, 61.8, 61.2, 57.8, 55.7, 
53.6, 51.6, 40.7, 40.0, 29.9, 23.7, 19.2, 13.0. LR-MS (APCI+): calcd. for C24H30N3O4+ [M+H]+: 424.5, 
found 424.8. 
 
Oxidation of MG derivatives to 7OH analogs  
General procedure E: Starting material (73 µmol) was dissolved in acetone (2.2 mL), sat. aq. NaHCO3 
(1.5 mL) was added, and the stirred suspension was cooled in an ice bath (0 °C). Oxone (1.4 – 1.5 equiv) 
in H2O (0.7 mL) was added dropwise over 20 min with vigorous stirring. (Care should be taken that the 
RM does not form lumps and should be stirred thoroughly). The reaction was monitored during the addition 
of oxone by TLC. After 25 min from the first addition, the RM was diluted with H2O (10 mL) and extracted 
with EtOAc (3 × 10 mL). The combined extracts were washed with brine (10 mL), dried over Na2SO4, and 




Compound 22 (11-F-7OH). The reaction was performed according to the general procedure E using SM 
15 (30 mg, 73 µmol) and oxone (22.1 mg, 109 µmol). The crude material was purified by PTLC 
(EtOAc:Hex 1:4 + 2% Et3N). Product 22 was obtained as a yellow solid (16 mg, 52%). 
1H NMR (400 MHz, CDCl3) δ 7.43 (s, 1H), 6.91 (dd, J = 8.5, 2.0 Hz, 1H), 6.45 (dd, J = 11.3, 2.0 Hz, 1H), 
3.84 (s, 3H), 3.80 (s, 3H), 3.69 (s, 3H), 3.12 (dd, J = 11.1, 2.6 Hz, 1H), 3.06 – 2.96 (m, 2H), 2.91 – 2.73 
(m, 3H), 2.66 – 2.56 (m, 2H), 2.51 – 2.43 (m, 1H), 1.89 – 1.82 (m, 1H), 1.73 – 1.53 (m, 3H), 1.30 – 1.14 
(m, 1H), 0.82 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 186.2, 169.4, 165.0 (d, J = 245.2 Hz), 
160.9, 156.2 (d, J = 11.8 Hz), 156.1 (d, J = 13.1 Hz), 122.3, 111.4, 102.2 (d, J = 24.4 Hz), 97.1 (d, J = 27.4 
Hz), 80.9, 61.9, 61.6, 58.3, 55.9, 51.5, 50.1, 40.6, 39.4, 36.1, 26.1, 19.1, 13.0. 19F (proton decoupled) NMR 






Compound 23 (11-Cl-7OH). The reaction was performed according to the general procedure E using SM 
16 (30 mg, 69 µmol) and oxone (30 mg, 97 µmol). The crude material was purified by repeated PTLC 
(EtOAc:Hex 1:3 + 2% Et3N and EtOAc:Hex 3:7 + 2% Et3N). Product 23 was obtained as a yellow solid 
(15 mg, 50%).   
1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 7.21 (d, J = 1.5 Hz, 1H), 6.73 (d, J = 1.5 Hz, 1H), 3.86 (s, 3H), 
3.81 (s, 3H), 3.70 (s, 3H), 3.14 – 2.97 (m, 3H), 2.93 (d, J = 7.4 Hz, 1H), 2.87 – 2.72 (m, 2H), 2.70 – 2.55 
(m, 2H), 2.48 (dd, J = 11.5, 3.0 Hz, 1H), 1.86 (d, J = 13.7 Hz, 1H), 1.75 – 1.54 (m, 3H), 1.33 – 1.17 (m, 
1H), 0.82 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 185.8, 169.2, 160.7, 155.8, 135.9, 125.1, 
114.9, 111.2, 109.6, 80.9, 61.8, 61.5, 58.1, 55.8, 49.9, 45.7, 40.5, 39.2, 35.8, 25.9, 18.9, 12.8. HRMS (ESI+) 
calcd. for C23H30ClN2O5+ [M+H]+: 449.1843, found 449.1842. 
 
 
Compound 24 (11-Br-7OH). The reaction was performed according to the general procedure E using SM 
17 (30 mg, 63 µmol) and oxone (25 mg, 82 µmol). The crude material was purified by repeated PTLC 
(EtOAc:Hex 1:3 + 2% Et3N and EtOAc:Hex 3:7 + 2% Et3N). Product 24 was obtained as a yellow solid 
(14 mg, 45%). 
1H NMR (400 MHz, CDCl3) δ 7.43 (s, 1H), 7.34 (d, J = 1.3 Hz, 1H), 6.87 (d, J = 1.3 Hz, 1H), 3.86 (s, 3H), 
3.80 (s, 3H), 3.69 (s, 3H), 3.15 – 2.96 (m, 3H), 2.84 – 2.71 (m, 2H), 2.65 – 2.56 (m, 2H), 2.51 – 2.44 (m, 
1H), 2.30 (s, 1H), 1.85 (dt, J = 13.7, 3.1 Hz, 1H), 1.73 – 1.56 (m, 3H), 1.30 – 1.18 (m, 1H), 0.82 (t, J = 7.3 
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 186.0, 169.4, 160.9, 156.1, 156.1, 125.8, 123.6, 118.0, 112.6, 
111.3, 81.1, 61.9, 61.7, 58.3, 56.0, 51.4, 50.0, 40.6, 39.4, 35.8, 26.1, 19.1, 13.0. HRMS (ESI+) calcd. for 











Activity of 11-X-7OH analogs at the human and rodent opioid receptors. 
A/  
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Supplementary Figure 7: Agonist activity of 11-X-7OH analogs at the human and mouse delta opioid 
receptor (hDOR and mDOR). hDOR and mDOR were co-expressed with GαoB, β1, γ2 and the BRET 
CAMYEL sensor. (A) Agonist activity at hDOR; positive control = [D-Pen2,5]-enkephalin (DPDPE) (B) 
Agonist activity at mDOR, positive control = DPDPE; Curves represent the average of n = 3, independent 

























































Supplementary Figure 8: Agonist activity of 11-X-7OH analogs at the human and rat kappa opioid 
receptor (hKOR and rKOR). hKOR and rKOR were co-expressed with GαoB, β1, γ2 and the BRET 
CAMYEL sensor. (A) Agonist activity at hKOR; positive control = U-50,488. (B) Agonist activity at 
rKOR, positive control = U-50,488; Curves represent the average of n = 3, independent experiments with 








Supplementary Figure 9: Antagonist activity of 11-Br-7OH (24) analog at the human and mouse delta 
opioid receptor (hDOR and mDOR). hDOR and mDOR were co-expressed with GαoB, β1, γ2 and the BRET 
CAMYEL sensor. (A) Antagonist activity at hDOR, competitive inhibition of [D-Pen2,5]-enkephalin 
(DPDPE), positive control = TIPP-psi. (B) Antagonist activity at mDOR, competitive inhibition of DPDPE, 
positive control = TIPP -psi. Curves represent the average of n = 3, independent experiments with error 
bars representing ±SEM. 
 
 































 + DPDPE (EC80)
TIPP-psi
11-Br-7OH (24)

























B /  
 
Supplementary Figure 10: Antagonist activity of 11-Br-7OH (24) analog at the human and rat kappa 
opioid receptor (hKOR and rKOR). hKOR and rKOR were co-expressed with GαoB, β1, γ2 and the BRET 
CAMYEL sensor. (A) Antagonist activity at hKOR, competitive inhibition of U-50,488 (EC80), positive 
control = nor-binaltorphimine (nor-BNI). (B) Antagonist activity at rKOR, competitive inhibition of U-
50,488 (EC80), positive control = TIPP-psi. Curves represent the average of n = 3, independent experiments 





Mouse Receptor Ki Determination. 
Materials: IBNtxA and [125I]BNtxA were synthesized at MSKCC as previously described.9–11  
Na125I was purchased from Perkin-Elmer (Waltham, MA). 
 
 Radioligand Competition Binding Assays with Mouse Receptors: [125I]BNtxA binding was 
carried out in membranes prepared from Chinese Hamster Ovary (CHO) cells stably expressing murine 
clones of MOR, DOR, and KOR, as previously described.9,10,12 Binding incubations were performed at 25 
°C for 90 min in 50 mM potassium phosphate buffer, pH 7.4, containing 5 mM magnesium sulfate. After 
the incubation, the reaction was filtered through glass-fiber filters (Whatman Schleicher & Schuell, Keene, 
NH) and washed three times with 3 mL of ice-cold 50 mM Tris-HCl, pH 7.4, on a semiautomatic cell 
harvester. Nonspecific binding was defined by addition of levallorphan (8 µM) to matching samples and 
was subtracted from total binding to yield specific binding. Ki values were calculated by nonlinear 











































regression analysis (GraphPad Prism, San Diego, CA). Protein concentrations were determined using the 
Lowry method with BSA as the standard.13  
 
CAMYEL BRET Assays. 
 
Materials. HEK-293T cells were obtained from the American Type Culture Collection (Rockville, 
MD, USA) and were cultured in a 5% CO2 atmosphere at 37 °C in Dulbecco's Modified Eagle Medium 
(high glucose no. 11965; Life Technologies; Grand Island, NY, USA) supplemented with 10% Fetal Bovine 
Serum and 100 U ml−1 penicillin and 100 μg ml−1 streptomycin (Corning). DAMGO and nor-BNI were 
purchased from Abcam (Cambridge, United Kingdom). Coelenterazine H was purchased from Dalton 
Pharma Services (Toronto, ON, Canada). Polyethylenimine (PEI) was purchased from Polysciences 
(Warrington, PA, USA). Forskolin was purchased from Sigma-Aldrich (Saint Louis, MO, USA). DPDPE, 
naloxone HCl, and (±)-U-50488 HCl were purchased from Tocris Biosciences (Minneapolis, MN, USA). 
TIPP[psi] was obtained from the National Institute on Drug Abuse Drug Supply Program. 
DNA Constructs. The mouse MOR (mMOR), the mouse DOR (mDOR) and the rat KOR (rKOR) 
were provided by Dr Lakshmi Devi at Mount Sinai School of Medicine. The human MOR (hMOR), human 
DOR (hDOR) and human KOR (hKOR) were obtained from the Missouri S&T Resource Center. The 
human G protein constructs used here have been previously described14 and were obtained from the 
Missouri S&T Resource Center unless otherwise noted. The G proteins used were: GαoB (GαoB), Gβ1 (β1), 
Gγ2 (γ2). YFP-Epac-RLuc (CAMYEL) was obtained from ATCC (no. MBA-277).15 All constructs were 
sequence confirmed. 
Transfection. A total of 20 μg of cDNA was transiently transfected into HEK-293T cells (6 × 
106 cells per plate) in 10 cm dishes (1.25 μg receptor, 10 μg CAMYEL, 1.25 μg GαoB, 1.25 μg β1, 1.25 μg 
γ2, and 5μg pcDNA3.1 empty vector) using PEI in a 1:1 ratio (diluted in Opti-MEM, Life Technologies). 
Cells were maintained in the HEK-293T media described above. After 24 h, the media was changed, and 
the experiment was performed 24 h later (48 h after transfection). 
Bioluminescence Resonance Energy Transfer (BRET). Experiments were performed as 
described previously.14,16–18 Briefly, transfected cells were dissociated and resuspended in phosphate-
buffered saline. Approximately 200,000 cells per well were added to a black-framed, white well 96-well 
plate (no. 60050; Perkin Elmer; Waltham, MA, USA). For agonist assays, 1 μM forskolin (cAMP 
accumulation) was added to each well. After 5 min, the luciferase substrate coelenterazine H (5 μM) was 
added to each well. Ligands were added after 5 min, then BRET signal was measured 5 min later. For 
antagonist assays, ligands were added first, then allowed to incubate for 20 min. Following antagonist 




each well. After another 5 min, full agonist ligands (DAMGO, DPDPE, or U-50,488 at EC80 concentration) 
were added to each well and the BRET signal was measured 5 min later. All BRET signal measurements 
were done on a PHERAstar FS plate reader (BMG Labtech, Cary, NC, USA). The BRET signal was 
calculated as the ratio of the light emitted by the energy acceptor, mVenus (510–540 nm), over the light 
emitted by the energy donor, RLuc8 (485 nm). Dose–response curves were fit using a three-parameter 
logistic equation in GraphPad Prism 5 (Graphpad Software, La Jolla, CA, USA). All experiments were 
repeated in three independent trials each with triplicate determinations. 
 
BRET-Based Nb33 Recruitment Assays. 
 
Materials: HEK-293T cells were obtained from the American Type Culture Collection (Rockville, 
MD, USA) and were cultured in a 5% CO2 atmosphere at 37 °C in Dulbecco's Modified Eagle Medium 
(DMEM, high glucose, #11965; Life Technologies; Grand Island, NY, USA) supplemented with 10% Fetal 
Bovine Serum (#35-010-CV, Corning, Corning, NY, USA) and 100 IU ml−1 penicillin and 100 μg ml−1 
streptomycin (#30-002-CI; Corning, Corning, NY, USA). The following chemicals were used without 
further modification: DAMGO (#78123-71-4, Abcam, Cambridge, United Kingdom), buprenorphine 
hydrochloride (#B9275, Sigma-Aldrich, St. Louis, MO, USA), morphine sulfate (#M1167, Spectrum 
Chemicals, New Brunswick, NJ, USA), coelenterazine H (#DC-001437, Dalton Pharma Services, Toronto, 
ON, Canada), PEI (#NC1014320, Polysciences, Warrington, PA, USA).  
DNA Constructs: The expression vector coding for mouse MOR tagged at the C-terminus with 
Nanoluc (mMOR-nluc) by a Gly-Ser linker was constructed using standard techniques in molecular biology 
and confirmed by DNA sequencing (Psomagen, Brooklyn, NY, USA). Briefly, two DNA inserts were PCR 
amplified, one coding for mMOR with an N terminal signal peptide followed by a FLAG tag, and the other 
coding for NanoLuc. The two inserts were joined by PCR amplification and the resulting insert coding 
mMOR-nluc was cloned into the Hind III and Xho I sites of pcDNA3.1 (+) (#V79020, ThermoFisher 
Scientific, Waltham, MA, USA). The plasmid coding for human MOR-nanoluc (hMOR-nluc) was a gift 
from Dr. Nevin Lambert at the Medical College of Georgia. The plasmid coding for the nanobody-33-
Venus (Nb-33) construct19 was a gift from Dr. Meritxell Canals at the University of Nottingham.  
Transfection: A total of 5 μg of cDNA was transiently transfected into HEK-293T cells (2 × 106 
cells per plate) in 10 cm dishes (1 μg receptor-nluc, and 4 μg Nb-33-Venus), using PEI in a 6:1 ratio (diluted 
in DMEM). Cells were maintained in the HEK-293T media described above. Experiments were performed 
48 h after transfection.  
BRET: Experiments were performed as described previously.20 Briefly, transfected cells were 




96-well plate (no. 60050; Perkin Elmer; Waltham, MA, USA). At time zero, the luciferase substrate 
coelenterazine H (5 μM) was added to each well. Ligands were added after 5 min, then BRET signal was 
measured 10 min later. BRET measurements were performed using a PHERAstar FS plate reader (BMG 
Labtech, Cary, NC, USA). The BRET signal was calculated as the ratio of the light emitted by the mVenus 
acceptor (510–540 nm) over the light emitted by the NanoLuc donor (475 nm). Dose–response curves were 
fit using a three-parameter logistic equation in GraphPad Prism 8 (Graphpad Software, La Jolla, CA, USA). 
All experiments were repeated in at least three independent trials each with triplicate determinations. 
 
Tail Flick Mice assay. 
Mice 
For analgesic dose-response experiments, male CD1 mice (20–32 g),6-8 weeks were obtained from Charles 
River Laboratories and male C57BL/6 mice (22–30 g), 8–15 weeks  were obtained from Jackson Lab (Bar 
Harbor, ME) and housed 5 mice per cage in a vivarium following an IACUC-approved protocol. For male 
C57BL/6 mice temperature was kept constant at 22 ± 2 °C, and relative humidity was maintained at 50 ± 
5%. For male CD1 mice (20–32 g) the temperature was in the range of 20-26 °C and relative humidity 
maintained within the range of 30-70%. Mice were given access to food and tap water ad libitum. All mice 
used throughout the manuscript were opioid naïve. All mice were maintained on a 12 h light/dark cycle 
with Purina rodent chow and water available ad libitum and housed in groups of five until testing.  
For analgesic testing in knockout animals, wild-type, male C57BL/6 mice (22–33 g), 10-12 weeks were 
purchased from the Jackson Lab (Bar Harbor, ME). These mice were kept at a constant temperature of 22 
± 2 °C, and relative humidity was maintained at 40-50%. Exon-1/Exon-11 MOR-1 KO mice on a C57 
background were bred in the Pintar laboratory at Rutgers University. All mice were maintained on a 12-
hour light/dark cycle with food and water available ad libitum, and housed in groups of five until testing. 
All testing was done in the light cycle. 
All animal studies were preapproved by the Institutional Animal Care and Use Committees of Washington 
University School of Medicine and Columbia University, in accordance with the 2002 National Institutes 
of Health Guide for the Care and Use of Laboratory Animals. 
 
Materials and Formulations 
Compounds 7OH and the analogs were prepared as described above. Compound solutions were prepared 
on the same day as testing from pure solid material. For the analgesic testing with the C57BL/6 mice the 
solids were dissolved in UPS grade 0.85% saline with addition of 2 molar equivalents of glacial acetic acid. 
For the analgesic testing with the CD1 mice solids were dissolved in 10:10:80 of DMSO: solutol: saline 




dilution series was prepared for the desired doses of 0.1, 0.3, 1, 3, and 10 mg/kg (concentrations 0.01 
mg/mL, 0.03 mg/mL,  0.1 mg/mL, 0.3 mg/mL, and 1 mg/mL respectively).  Solutions were filtered through 
a PTFE 0.45𝜇m syringe filter and administered s.c. at a max volume of 300𝜇L. 
 
Tail Flick (Dose – response) 
Tail flick antinociception was determined using the radiant heat tail flick technique using an Ugo Basile 
model 37360 instrument as previously described.21,22 The intensity was set to achieve a baseline between 2 
and 3 s. Baseline latencies were determined before experimental treatments for all mice. Tail flick 
antinociception was assessed as an increase in baseline latency, with a maximal 15 s latency to minimize 
damage to the tail. Data were analyzed as percent maximal effect, %MPE, and was calculated according to 
the formula: % MPE = [(observed latency – baseline latency)/(maximal latency – baseline latency)] × 100. 
Compounds were injected subcutaneously (s.c.) and antinociception was assessed at the peak effect. Mice 
were tested for analgesia with cumulative subcutaneous doses of the drug until the mouse can withstand the 
maximal latency. Once the mouse reached the maximal latency, the mouse was no longer given higher 
doses. The analgesia experiments were performed by blinding the experimenter to the identity of 7OH 
versus 11-F-7OH. In vivo experiments were evaluated using GraphPad Prism 8, San Diego, CA as described 
above.  
 
Tail Flick (KO animals) 
Analgesia was tested in wild-type and MOR KO animals by the radiant heat tail-flick technique using an 
IITC Model 33 Tail Flick Analgesia Meter as previously described.23 The intensity was set to achieve a 
baseline between 2 and 3 s. Tail flick antinociception was assessed as an increase in baseline latency, with 
a maximal 10 s latency to minimize damage to the tail. Data were analyzed as percent maximal effect, 
%MPE, which was calculated according to the formula: % MPE [(observed latency − baseline 
latency)/(maximal latency − baseline latency)] × 100. Compounds were administered subcutaneously (s.c.) 
as indicated in the figures, and analgesia was assessed at the peak effect (15 min). Mice were tested for 
analgesia with cumulative subcutaneous doses of the drug until the mouse can withstand the maximal 
latency. Once the mouse reached the maximal latency, the mouse was no longer given higher doses. In vivo 
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PG: protecting group 
RT: Room Temperature 
RM: Reaction Mixture 
TLC: Thin layer Chromatography 
SM: Starting Material 
PTLC: Preparative Thin Layer Chromatography 















Supplementary Figure 11 : 1H-NMR of  Boc-MG 
 
 
























































































































































































































































































































































































Supplementary Figure 13 : 1H-NMR of 12-Br-MG (3) 
 





























































































































































































































































































































































Compound 3 (12-Br-MG) 




Supplementary Figure 15 : 1H-NMR of Dihydromitragynine (DHM) 
 
 













































































































































































































































































































































































Supplementary Figure 17 : 1H-NMR of MG EG (4) 
 
 














































































































































































































































































































































































































Supplementary Figure 19 : 1H-NMR of 4 and 5 (mixture) 
 














































































































































































































































































































































































































































































































































































Compound 5 (11-BrMG-EG). 




Supplementary Figure 21 : 13C-NMR of 11-Br-MG EG (5) 
 































































































































Compound 5 (11-BrMG-EG). 
























































































































































































































































Supplementary Figure 22 : 13C-NMR of 11-F-MG EG (7) 
 











































































































































































Supplementary Figure 24 : 1H-NMR of 11-I-MG EG (8) 
 






























































































































































































































































































































































































































Supplementary Figure 26 : 1H-NMR of 11-CH3-MG EG (9) 
 




































































































































































































































































































































































































Supplementary Figure 28 : 1H-NMR of 11-Ph-MG EG (10) 
 
















































































































































































































































































Compound 10 (11-phenyl-MG-EG). 













































































































































Supplementary Figure 30 : 1H-NMR of 11-CONH2-MG EG (11) 
 



























































































































































































































































































































































































Supplementary Figure 32 : 1H-NMR of 11-CN-MG EG (12) 
 















Compound 12 (11-CN-MG-EG.HCl salt)







































































































































































































































































Compound 12 (11-CN-MG-EG.HCl salt)
















































































































Supplementary Figure 34 : 1H-NMR of 11-Cl-MG EG (13) 
 











































































































































































































































































































































Supplementary Figure 36 : 1H-NMR of 11-OH-MG EG (14) 
 





























































































































































































































































































































































































Supplementary Figure 38 : 1H-NMR of 11-OTf-MG EG (14a) 
 


















































































































































































































































































































































































































Supplementary Figure 40 : 19F-NMR of 11-OTf-MG EG (14a) 
 





















































































































































































































































































































Supplementary Figure 42 : 13C-NMR of 11-SnBu3-MG EG (14b) 
 
































































































































Compound 15 (11-F-MG )













































































































































































































































Supplementary Figure 44 : 13C-NMR of 11-F-MG (15) 
 










Compound 15 (11-F-MG )





































































































































































Compound 15 (11-F-MG )




Supplementary Figure 46 : 1H-NMR of 11-Cl-MG (16) 
 



























































































































































































































































































































































Supplementary Figure 48 : 1H-NMR of 11-Br-MG (17) 
 





















































































































































































































































































































































































Supplementary Figure 50 : 1H-NMR of 11-CH3-MG (18) 
 

























































































































































































































































































































































































































Supplementary Figure 52 : 1H-NMR of 11-CH3-MG (19) 
 
































































































































































































































































































































































































Supplementary Figure 54 : 1H-NMR of 11-CONH2-MG (20) 
 


















































































































































































































































































































































Supplementary Figure 56 : 1H-NMR of 11-CN-MG (21) 
 





































































































































































































































































































































































Supplementary Figure 58 : 1H-NMR of 11-F-7OH (22) 
 












































































































































































































































































































































































































Supplementary Figure 60 : 19F-NMR of 11-F-7OH (22) 
 






















































































































































































































































































Supplementary Figure 62 : 13Cl-NMR of 11-Cl-7OH (23) 
 
















































































































































































































































































































































































Supplementary Figure 64 : 13C-NMR of 11-Cl-7OH (23) 
 
































































































































































































































Supplementary Figure 66 : 1H-NMR of 12-Br-7OH (3) 
 














































































































































































Compound 3 (12-Br-MG) (Synthesized from NBS)




















































































































Compound 3 (12-Br-MG) (Synthesized from NBS) 
13C NMR (126 MHz, CDCl3)
